<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03802695</url>
  </required_header>
  <id_info>
    <org_study_id>OGFT001-001</org_study_id>
    <nct_id>NCT03802695</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of Engineered Donor Grafts (OrcaGraft) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies</brief_title>
  <official_title>A Phase 1, Dose Escalation and Expansion Study of Engineered Donor Grafts Derived From Mobilized Peripheral Blood (OrcaGraft), With Single Agent Graft Versus-host Disease Prophylaxis, in Recipients Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orca Biosystems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orca Biosystems, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts
      (&quot;OrcaGraft&quot;) in participants undergoing myeloablative allogeneic hematopoietic cell
      transplant transplantation for hematologic malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 8, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities (DLTs)</measure>
    <time_frame>From day of transplant through day +28 post-transplant</time_frame>
    <description>Incidence of dose limiting toxicities (DLTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of primary graft failure</measure>
    <time_frame>From day of transplant (Day 0) through day +28 post-transplant</time_frame>
    <description>Incidence of primary graft failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and timing of neutrophil engraftment</measure>
    <time_frame>Day 0 through Day +28</time_frame>
    <description>Incidence and timing of neutrophil engraftment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and timing of platelet engraftment</measure>
    <time_frame>Day 0 through Day +50</time_frame>
    <description>Incidence and timing of platelet engraftment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of secondary graft failure through Day +100</measure>
    <time_frame>Day 0 through Day +100</time_frame>
    <description>Incidence of secondary graft failure through Day +100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent adverse events (TEAEs) through the safety reporting period</measure>
    <time_frame>Day 0 through Day +100</time_frame>
    <description>incidence, timing, and severity of TEAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute graft versus host disease (aGVHD)</measure>
    <time_frame>Day 0 through Day +100</time_frame>
    <description>incidence, timing, and severity of aGVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroid-refractory aGVHD</measure>
    <time_frame>Day 0 through Day +100</time_frame>
    <description>Incidence of steroid-refractory acute GVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic GVHD (cGVHD)</measure>
    <time_frame>Day 0 through Day +365</time_frame>
    <description>incidence, timing, and severity of cGVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Transplant Lymphoproliferative Disorder (PTLD)</measure>
    <time_frame>Day 0 through Day +365</time_frame>
    <description>incidence, timing, and severity of PTLD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-relapse mortality (NRM)</measure>
    <time_frame>Day 0 through Day +365</time_frame>
    <description>Incidence of non-relapse mortality (NRM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of disease relapse</measure>
    <time_frame>Day 0 through Day +365</time_frame>
    <description>Incidence of disease relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>Day 0 through Day +365</time_frame>
    <description>Disease-free survival is the time from date of transplant to death or relapse, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Day 0 through Day +365</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">113</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Acute Leukemia</condition>
  <arm_group>
    <arm_group_label>Related and unrelated HLA-matched donors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Haploidentical donors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OrcaGraft</intervention_name>
    <description>engineered donor allograft</description>
    <arm_group_label>Haploidentical donors</arm_group_label>
    <arm_group_label>Related and unrelated HLA-matched donors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Age ≥ 18 and ≤ 65 years at the time of enrollment

          2. Diagnosed acute myeloid, lymphoid or mixed phenotype leukemia in complete remission
             (CR) or CR with incomplete hematologic recovery (CRi) or

          3. High or very high risk myelodysplasic syndrome (MDS) including both of the following:

          4. Planned to undergo myeloablative allogeneic hematopoietic stem cell transplant (HCT)

          5. Matched to a related or unrelated donor or to a haploidentical donor

          6. Estimated glomerular filtration rate (eGFR) &gt; 50 mL/minute

          7. Cardiac ejection fraction at rest ≥ 45% or shortening fraction of ≥ 27% by
             echocardiogram or radionuclide scan (MUGA)

          8. Diffusing capacity of the lung for carbon monoxide (DLCO) (adjusted for hemoglobin) ≥
             50%

          9. Total bilirubin &lt; 1.5 times upper limit of normal (ULN) (&lt; 3 times if attributed to
             Gilbert's syndrome) and ALT/AST &lt; 3 times ULN

        Key Exclusion Criteria:

          1. Prior allogeneic HCT

          2. Currently receiving corticosteroids or other immunosuppressive therapy. Topical
             corticosteroids or oral systemic corticosteroid doses less than or equal to 10 mg/day
             are allowed.

          3. Planned donor lymphocyte infusion (DLI)

          4. Positive anti-donor HLA antibodies against a mismatched allele in the selected donor

          5. Karnofsky performance score &lt; 70% (Appendix 12.7)

          6. Hematopoietic cell transplantation-specific Comorbidity Index (HCT-CI) &gt; 4 (Appendix
             12.8)

          7. Uncontrolled bacterial, viral or fungal infections (currently taking antimicrobial
             therapy and with progression or no clinical improvement) at time of enrollment

          8. Seropositive for HIV-1 or -2, HTLV-1 or -2

          9. Any uncontrolled autoimmune disease requiring active immunosuppressive treatment

         10. Concurrent malignancies or active disease within 1 year, except non-melanoma skin
             cancers that have been curatively resected

         11. History of idiopathic or secondary myelofibrosis

         12. Women who are pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James S McClellan, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Orca Biosystems, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James S McClellan, MD, PhD</last_name>
    <phone>1-530-414-9743</phone>
    <email>info@orcabiosystems.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James S McClellan, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James S McClellan, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford Health Care</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James S McClellan, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James S McClellan, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott S McClellan, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott S McClellan, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James S McClellan, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Froedtert Memorial Lutheran Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James S McClellan, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>January 10, 2019</study_first_submitted>
  <study_first_submitted_qc>January 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2019</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

